Skip to main content
 Home
  • Dansk
  • English

Servicemenu

  • News
  • Events
    • Previous Events
  • Themes
  • Contact
    • Contact Grants & Prizes
    • Press Contact
    • Contact The Lundbeck Foundation
    • Departments
    • Logo and Design

Hovedmenu

  • Business Activities
    • Lundbeckfonden BioCapital
      • About Lundbeckfonden BioCapital
      • Lundbeckfonden BioCapital News
      • Lundbeckfonden BioCapital Portfolio
      • Lundbeckfonden BioCapital Portfolio News
    • Strategic Investments
      • Long-Term Value Creation
      • Strategic Ownership
    • Invest
  • Grants & Prizes
    • For applicants
      • Apply for grants
      • Processing of applications
      • Review Panels
    • For grant recipients
      • Terms and Conditions - Research Grants
      • Reporting
      • Distribution of funds
    • What we have funded
      • Fellowships
      • Professorships
      • Ascending Investigators
      • Pre-Graduate Scholarships
      • LF Postdocs
      • Visiting Professorships
      • LF Experiment
      • Talentpriser
      • The Brain Prize
      • Young Investigator Prize
      • Alle
    • News - Grants & Prizes
    • Research Stories
  • Neurotorium
  • The Brain Prize
    • Overview
    • Nominations & Selection Process
    • Press and Logo
    • News
  • About Us
    • The Organisation
      • Board of Directors and Management
      • Vacancies
    • Who are we?
    • History and Statutes
    • Strategy and Purpose
      • Bringing Discoveries to Lives
    • Social Responsibility and Transparency
      • Recommendations on Foundation Governance, Corporate Governance and Transparency
      • Governance
      • Active voice in public debate
      • Policies
      • Whistleblower
    • Publikationer
      • Annual Reports
      • Sustainability Reports
      • The Magazine
      • Anniversary Book
  • Apply and Nominate

Hovedmenu - mobil

  • Business Activities
    • Lundbeckfonden BioCapital
      • About Lundbeckfonden BioCapital
      • Lundbeckfonden BioCapital News
      • Lundbeckfonden BioCapital Portfolio
      • Lundbeckfonden BioCapital Portfolio News
    • Strategic Investments
      • Long-Term Value Creation
      • Strategic Ownership
    • Invest
  • Grants & Prizes
    • For applicants
      • Apply for grants
      • Processing of applications
      • Review Panels
    • For grant recipients
      • Terms and Conditions - Research Grants
      • Reporting
      • Distribution of funds
    • What we have funded
      • Fellowships
      • Professorships
      • Ascending Investigators
      • Pre-Graduate Scholarships
      • LF Postdocs
      • Visiting Professorships
      • LF Experiment
      • Talentpriser
      • The Brain Prize
      • Young Investigator Prize
      • Alle
    • News - Grants & Prizes
    • Research Stories
  • Neurotorium
  • The Brain Prize
    • Overview
    • Nominations & Selection Process
    • Press and Logo
    • News
  • About Us
    • The Organisation
      • Board of Directors and Management
      • Vacancies
        • Personal Data Policy for Recruitment
    • Who are we?
    • History and Statutes
    • Strategy and Purpose
      • Bringing Discoveries to Lives
    • Social Responsibility and Transparency
      • Recommendations on Foundation Governance, Corporate Governance and Transparency
      • Governance
      • Active voice in public debate
      • Policies
      • Whistleblower
    • Publikationer
      • Annual Reports
      • Sustainability Reports
      • The Magazine
      • Anniversary Book
  • Apply and Nominate

Servicemenu - mobil

  • News
  • Events
    • Previous Events
  • Themes
  • Analyser
  • Contact
    • Contact Grants & Prizes
    • Press Contact
    • Contact The Lundbeck Foundation
    • Departments
    • Logo and Design
  • Dansk
  • English

Breadcrumb

  1. Home
  2. Business Activities
  3. Lundbeckfonden BioCapital
  4. Curzion Pharmaceuticals

Curzion Pharmaceuticals

Curzion was developing a compound for Diffuse cutaneous systemic sclerosis (dcSSc), a rare, chronic autoimmune disease marked by fibrosis, or skin thickening, in areas including hands, forearms, upper arms and thighs.

The compound was approaching phase 2b studies.

Related news about Curzion Pharmaceuticals

  • Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product Candidate to Expand Development-Stage Pipeline
Curzion logo

Lundbeckfonden BioCapital

Invested
2019

Acquired by Horizon in 2020

Location

San Diego, USA

Footer logo
The Lundbeck Foundation annually distributes more than DKK 500 mio. to Danish-based healthcare science research, primarily with a focus on the brain.

Lundbeckfonden
Scherfigsvej 7
2100 København Ø

CVR
11814913

Links

  • Cookie-Policy
  • Disclaimer & Privacy
  • History and Statutes
  • Our Strategy
  • Events
  • Contact
  • Jobs
Follow us
Facebook
Twitter
LinkedIn
Youtube